FDA Urged To Pull Eisai's High-Dose Aricept
A nonprofit consumer advocacy group urged the U.S. Food and Drug Administration on Wednesday to immediately yank the highest dose of Alzheimer's disease drug Aricept from the market due to its...To view the full article, register now.
Already a subscriber? Click here to view full article